Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals. The TCDA average annual return since 2018 is shown above.
The Average Annual Return on the TCDA average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TCDA average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TCDA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|